SPOTLIGHT: Baxter bullish on Gammagard


Baxter International says that a preliminary analysis of data from a Phase II study of Gammagard for Alzheimer's has produced enough encouraging signs to lay the groundwork for Phase III. The next study should get underway in early 2008. Release

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.